Seattle Genetics, Takeda's Cancer Drug Meets Main Goal In Trial

September 29, 2014 12:55 PM

5 0

Seattle Genetics, Takeda's Cancer Drug Meets Main Goal In Trial

(Reuters) - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer.

Consolidation therapy is given to cancer patients who have undergone initial therapy and kills any cancer cells that may be left in the body.

Also read: FDA approves drug for primary progressive multiple sclerosis

Read more

To category page

Loading...